IP Library Granted Patent US 11,419,659
Granted Patent B2
US 11,419,659 · App. 16/438,362 · Granted Aug 23, 2022

Heat ablation systems, devices and methods for the treatment of tissue

Inventors: Philip S. Levin (Storrs, CT); Jay Caplan (Belmont, MA); Harith Rajagopalan (Wellesley Hills, MA); Mark A. Manasas (Lexington, MA); Andrew Coats (Somerville, MA); J. Christopher Flaherty (Auburndale, FL)
Assignee: Fractyl Health, Inc.
A61B18/082A61B18/04A61B18/1492A61B2018/0022A61B2018/00023A61B2018/0025A61B2018/00214A61B2018/00482A61B2018/00494A61B2018/00577A61B2018/00648A61B2018/00744A61B2018/044A61B2018/046A61M25/04A61M2025/1013F04C2270/0421
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,419,659
App. No.
16/438,362
Granted
Aug 23, 2022
Kind
B2
Abstract

A system for treatment target tissue comprises an ablation device and an energy delivery unit. The ablation device comprises an elongate tube with an expandable treatment element. The system delivers a thermal dose of energy to treat the target tissue. Methods of treating target tissue are also provided.

Claims (28)

1. A system for treating target tissue, the system comprising:

(1) an ablation device comprising:

an elongate tube with a proximal portion, a distal portion, and at least one lumen extending from the proximal portion to the distal portion; and

an expandable treatment element mounted to the elongate tube distal portion and in fluid communication with the at least one lumen; and

(2) an energy delivery unit constructed and arranged to deliver a thermal dose to the target tissue by (a) delivering a heated fluid to the expandable treatment element to ablate the target tissue, (b) applying a negative pressure to remove the heated fluid from the expandable treatment element, and (c) subsequently delivering a cooling fluid to the expandable treatment element to cool the target tissue, wherein the cooling fluid is delivered to the expandable treatment element at a temperature at least 10° C. below the temperature of the heated fluid.

2. The system according to claim 1 , wherein the energy delivery unit is configured to provide emptying cycles by applying the negative pressure between heating and cooling cycles.

3. The system according to claim 1 , wherein the heating fluid, the cooling fluid, and the negative pressure are delivered through the at least one lumen in the elongate tube.

4. The system according to claim 1 , wherein the at least one lumen comprises a first lumen for the delivery of fluid to the expandable treatment element, and a second lumen for the removal of fluids from the expandable treatment element.

5. The system according to claim 1 , wherein the delivery of the heated fluid comprises circulating heated fluid through the expandable treatment element.

6. The system according to claim 5 , wherein the heated fluid is maintained at a relatively constant temperature while in the expandable treatment element.

7. The system according to claim 6 , wherein the heated fluid is maintained at a temperature between 65° C. and 99° C.

8. The system according to claim 1 , wherein the system is constructed and arranged to deliver multiple thermal doses of energy to the target tissue.

9. The system according to claim 8 , wherein a first dose is delivered to a first tissue location and a second dose is delivered to a second tissue location.

10. The system according to claim 1 , further comprising an inflow port and an outflow port, the inflow port and outflow port in fluid communication with the expandable treatment element.

11. The system according to claim 1 , wherein the thermal dose is constructed and arranged to ablate duodenal mucosa while avoiding damage to the duodenal serosa.

12. The system according to claim 1 , wherein the system is further constructed and arranged to thermally prime the expandable treatment element.

13. The system according to claim 1 , wherein the system is further constructed and arranged to inflate the expandable treatment element within 10 seconds.

14. The system according to claim 1 , wherein the heated fluid and/or the cooling fluid is delivered at a relatively constant temperature.

15. The system according to claim 14 , wherein the heated fluid is delivered at a temperature of approximately 65° C. for approximately 30 seconds to 60 seconds.

16. The system according to claim 14 , wherein the heated fluid is delivered a temperature of approximately 70° C. for approximately 5 seconds to 45 seconds.

17. The system according to claim 14 , wherein the heated fluid is delivered at a temperature of approximately 75° C. for approximately 3 seconds to 40 seconds.

18. The system according to claim 14 , wherein the heated fluid is delivered at a temperature of approximately 80° C. for approximately 3 seconds to 30 seconds.

19. The system according to claim 14 , wherein the heated fluid is delivered at a temperature of approximately 90° C. for approximately 3 seconds to 20 seconds.

20. The system according to claim 1 , wherein the system comprises a thermal response time such that the thermal dose temperature reaches 90% of a modified target temperature within 15 seconds of initiating a change to the modified target temperature.

21. The system according to claim 1 , wherein the cooling fluid is delivered at a temperature of less than 37° C.

22. The system according to claim 1 , wherein the cooling fluid is delivered at a temperature of less than 10° C.

23. The system according to claim 1 , wherein the cooling fluid is delivered for at least 15 seconds.

24. The system according to claim 1 , wherein the delivering of the cooling fluid is configured to cool the target tissue to a temperature of less than 43° C.

Assignments (3)
SECURITY INTEREST Recorded Sep 7, 2023
From: FRACTYL HEALTH, INC.
To: SYMBIOTIC CAPITAL AGENCY LLC
Reel/Frame 064840/0561 →
CHANGE OF NAME Recorded Oct 1, 2021
From: FRACTYL LABORATORIES, INC.
To: FRACTYL HEALTH, INC.
Reel/Frame 057688/0747 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 16, 2020
From: LEVIN, PHILIP S.; CAPLAN, JAY; RAJAGOPALAN, HARITH; MANASAS, MARK A.; COATS, ANDREW; FLAHERTY, J. CHRISTOPHER
To: FRACTYL LABORATORIES, INC.
Reel/Frame 051540/0854 →
Continuity (4)
Continuation 14470503 · Aug 27, 2014
Continuation PCTUS2013028082 · Feb 27, 2013
Provisional Application 61603475 · Feb 27, 2012
Related Publication 20200138505A1 · May 7, 2020
Cited By (5)
US 12,186,011 US 12,201,342 US 12,239,365 US 12,426,948 US 12,690,909